Incidence of pneumococcal infections among children under 15 years in southern Catalonia throughout the heptavalent conjugate vaccine era, 2002–2009
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Updating epidemiological studies to document current incidences of pneumococcal diseases are greatly needed in the current era of new pneumococcal conjugate vaccines (PCVs). The aim of this study is to analyze the incidence and distribution of different serotypes causing pneumococcal infections among the pediatric population in southern Catalonia, Spain, throughout the 2002–2009 PCV7 eras.
A population-based surveillance study was conducted among children aged ≤14 years in the region of Tarragona (Catalonia, Spain) during the period 2002–2009. All cases of pneumococcal infections (invasive and non-invasive cases) were included in the study. Incidence rates (per 100,000 population-year) and prevalence of infections caused by serotypes included in different PCV formulations were calculated for the 2002–2005 and 2006–2009 periods.
Globally, across the total 2002–2009 period, the incidence of pneumococcal infections was 48.2 per 100,000 children-year (22.4 and 25.8 for invasive and non-invasive infections, respectively). Between 2002–2005 and 2006–2009, the incidence rates largely decreased among children aged <2 years (from 171 to 111 per 100,000 children-year; p = 0.059), but they did not substantially vary among children aged 2–14 years. The percentages of cases caused by serotypes included in PCV7 (60.0 vs. 16.7 %; p < 0.001), PCV10 (75.0 vs. 47.4 %; p = 0.028), and PCV13 (85.0 vs. 70.5 %; p = 0.190) decreased in both periods.
In this study, which was conducted in a setting with intermediate PCV7 uptakes, a considerable protective direct effect of vaccination occurred among young infants, but an indirect protective effect did not emerge in the rest of the pediatric population. Despite new PCVs with higher serotype coverage, an important proportion of pneumococcal infections is still not covered by these vaccines.
- Ortqvist A, Hedlund J, Kalin M. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Semin Respir Crit Care Med. 2005;26:563–74. CrossRef
- Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, The Northern California Kaiser Permanente Vaccine Study Center Group, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19:187–95. CrossRef
- Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737–46. CrossRef
- Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease–United States, 1998–2003. Morb Mortal Wkly Rep. 2005;54:893–7.
- Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Active Bacterial Core Surveillance/Emerging Infections Program Network, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32–41. CrossRef
- Centers for Disease Control and Prevention. Progress in introduction of pneumococcal conjugate vaccine worldwide, 2000–2008. Morb Mortal Wkly Rep. 2008;57:1148–51.
- Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297:1784–92. CrossRef
- Hicks L, Harrison L, Flannery B, Hadler JL, Schaffner W, Craig AS, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in United States during the era of widespread PCV7 vaccination, 1998–2004. J Infect Dis. 2007;196:1346–54. CrossRef
- Croxtall JD, Keating GM. Pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix; PHiD-CV). Paediatr Drugs. 2009;11:349–57. CrossRef
- Paradiso PR. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children. Clin Infect Dis. 2011;52:1241–7. CrossRef
- Vila Córcoles A, de Diego Cabanes C, Salsench Serrano E, Saún Casas N. Cover with conjugated heptavalent pneumococcal vaccine in the child population of Tarragona-Valls, Spain (in Spanish). Aten Primaria. 2007;39:507. CrossRef
- Web de l’estadística oficial de Catalunya. Idescat. Available at: http://www.idescat.cat. Accessed 20 Feb 2011.
- Fenoll A, Granizo JJ, Aguilar L, Giménez MJ, Aragoneses-Fenoll L, Hanquet G, et al. Temporal trends of invasive Streptococcus pneumonia serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol. 2009;47:1012–20. CrossRef
- Hanquet G, Kissling E, Fenoll A, George R, Lepoutre A, Lernout T, et al. Pneumococcal serotypes in children in 4 European countries. Emerg Infect Dis. 2010;16:1428–39. CrossRef
- Guevara M, Barricarte A, Gil-Setas A, García-Irure JJ, Beristain X, Torroba L, et al. Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clin Microbiol Infect. 2009;15:1013–9. CrossRef
- Barricarte A, Gil-Setas A, Torroba L, Castilla J, Petit A, Polo I, et al. Invasive pneumococcal disease in children younger than 5 years in Navarra, Spain (2000–2005). Impact of the conjugate vaccine (in Spanish). Med Clin (Barc). 2007;129:41–5. CrossRef
- Salleras L, Domínguez A, Ciruela P, Izquierdo C. Grupo de Trabajo del Sistema de Notificación Microbiológica de Cataluña. Impact of 7-valent pneumococcal conjugate vaccination in a population with low to intermediate vaccination levels (in Spanish). Enferm Infecc Microbiol Clin. 2009;27:275–7. CrossRef
- Aristegui J, Bernaola E, Pocheville I, García C, Arranz L, Durán G, et al. Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis. 2007;26:303–10. CrossRef
- Muñoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia–Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008;46:174–82. CrossRef
- Picazo J, Ruiz-Contreras J, Casado-Flores J, Giangaspro E, Del Castillo F, Hernández-Sampelayo T, et al. Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar. Clin Vaccine Immunol. 2011;18:89–94. CrossRef
- de Sevilla MF, García-García JJ, Esteva C, Moraga F, Hernández S, Selva L, et al. Clinical presentation of invasive pneumococcal disease in Spain in the era of heptavalent conjugate vaccine. Pediatr Infect Dis J. 2012;31:124–8. CrossRef
- Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010; 7. pii:e1000348.
- Salleras L, Domínguez A, Ciruela P, Izquierdo C, Navas E, Torner N, et al. Changes in serotypes causing invasive pneumococcal disease (2005–2007 vs. 1997–1999) in children under 2 years of age in a population with intermediate coverage of the 7-valent pneumococcal conjugated vaccine. Clin Microbiol Infect. 2009;5:97–1001.
- Imöhl M, Reinert RR, van der Linden M. Temporal variations among invasive pneumococcal disease serotypes in children and adults in Germany (1992–2008). Int J Microbiol. 2010;2010:874189.
- Park IH, Pritchard DG, Cartee R, Brandao A, Brandileone MC, Nahm MH. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol. 2007;45:1225–33. CrossRef
- Incidence of pneumococcal infections among children under 15 years in southern Catalonia throughout the heptavalent conjugate vaccine era, 2002–2009
Volume 41, Issue 2 , pp 439-446
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Streptococcus pneumoniae
- Pneumococcal infection
- Pneumococcal conjugate vaccine
- Serotype coverage
- Industry Sectors
- Author Affiliations
- 1. EPIVAC Study Group, Primary Care Service of Tarragona, Institut Catala de la Salut, Prat de la Riba 39, 43001, Tarragona, Spain
- 2. Department of Laboratory and Microbiology, Joan XXIII Hospital, Dr. Mallafré I Guasch, 4, 43007, Tarragona, Spain
- 3. Department of Otorhinolaryngology, Joan XXIII Hospital, Dr. Mallafré I Guasch, 4, 43007, Tarragona, Spain
- 4. Department of Laboratory and Microbiology, Santa Tecla Hospital, Rambla Vella, 14, 43003, Tarragona, Spain
- 5. IDIAP Jordi Gol Foundation, Gran Via Corts Catalanes, 587, 08007, Barcelona, Spain